The most iconic psychedelic — a semi-synthetic molecule active in millionths of a gram. What it is, how it works, the experience, its extraordinary history, and the landmark clinical trials underway.
LSD (lysergic acid diethylamide, "LSD-25," or "acid") is a semi-synthetic compound in the lysergamide family, derived from alkaloids of ergot — a fungus (Claviceps purpurea) that grows on rye and grains.
It is one of the most potent psychoactive substances known, active in the microgram range — millionths of a gram. A typical dose (~100 µg) is invisible, roughly the weight of a speck of dust; this extreme potency is one of LSD's defining pharmacological features. It's also famous for its long duration — a full experience runs about 8–12 hours, far longer than psilocybin or DMT.
Built in the lab from ergot's natural lysergic acid — first made by Albert Hofmann in 1938.
Active in micrograms; among the most potent psychoactive molecules ever discovered.
~8–12 hours, typically with a clear-headed, analytical, "electric" quality rather than dreamy sedation.
Like the other classic psychedelics, LSD's core action is on the serotonin system — but it has a uniquely "sticky" mechanism that explains its marathon duration.
LSD is a potent agonist at serotonin 5-HT2A receptors in the cortex — the core driver of the psychedelic effect, just as with psilocybin and DMT.
Crystal-structure work showed LSD slips into the receptor and an extracellular "lid" folds over it, trapping it in place. This unusually long binding is why a single dose lasts many hours.
Beyond 5-HT2A, LSD also engages other serotonin receptors and dopamine and adrenergic systems — part of why its character differs from psilocybin's.
It quiets the Default Mode Network (the self-referential "me" network) and increases global brain connectivity — the basis of ego dissolution and novel perspective.
Like the others, it rapidly raises BDNF and promotes synaptic growth, opening a window of heightened plasticity — the leading mechanism of therapeutic interest.
Tolerance builds almost immediately — a second dose the next day does little. This self-limiting quality discourages daily use.
The classic form — LSD solution dried onto small squares of perforated, often illustrated paper. Placed on/under the tongue.
LSD dissolved in a carrier, dosed by drop. Potent and easy to mis-measure — a real risk factor.
LSD in small gelatin squares or tiny pressed pills.
Microdose ~5–20 µg (sub-perceptual) · threshold/light ~25–75 µg · common ~100–200 µg · strong 200 µg+. Onset ~20–60 min, peak ~2–4 h, total ~8–12 h.
An LSD experience unfolds slowly and lasts most of a day. Compared with psilocybin it's often described as more "electric," analytical, and energizing — busier in the mind, with a strong push toward thought, connection-making, and pattern recognition.
Onset within ~20–60 minutes: a building sense of energy and anticipation, sharpening colours, edges beginning to breathe, mood lifting or nervous jitters.
Full perceptual alteration — flowing visuals, geometric patterning, synesthesia (seeing sound, hearing colour), profoundly altered sense of time, intensified meaning and emotion, and at higher doses ego dissolution and mystical-type states.
Effects level off into a long, often reflective and talkative stretch — creative thinking, insight, and emotional processing. Music can feel transcendent.
A gradual return, sometimes with residual stimulation that makes sleep hard. Many report a next-day "afterglow" of openness, calm and clarity.
The same dose can produce ecstasy or terror depending on two variables clinicians control tightly:
Your mood, expectations, intention, and psychological state going in. Anxiety, resistance, or unresolved distress tends to amplify; a grounded, open, "trust and let go" stance tends to smooth the experience.
The physical and social space. A calm, safe, familiar place with a trusted sober companion supports insight; a chaotic or unsafe setting invites fear. The clinical model uses a comfortable room, eyeshades, and curated music.
Visual flow and geometry, breathing surfaces, trails, intensified colour, synesthesia.
Rapid associative thinking, pattern recognition, novel connections, creative and philosophical insight.
Amplified feeling — awe, joy, love, but also anxiety or grief; emotions surface vividly and move quickly.
Loosening of the ego and self-narrative, up to full ego dissolution and unity/mystical-type experiences at high doses.
Microdosing means taking sub-perceptual amounts (~5–20 µg) on a periodic schedule — not enough to trip, intended to subtly lift mood, focus, creativity or energy over time. Popularized by James Fadiman, it's become widely practised.
The honest evidence picture: anecdotal reports are enthusiastic, but controlled trials are weak and mixed, and several placebo-controlled studies suggest much of the reported benefit may be expectation/placebo. It's an active research area, not a settled one. Practical cautions: LSD's rapid tolerance means dosing is spaced out; long-term effects of repeated low doses aren't well studied; and ergot-derived compounds warrant caution for anyone with cardiovascular concerns.
Swiss chemist Albert Hofmann at Sandoz synthesizes LSD-25 — the 25th in a series of lysergic-acid compounds — while researching circulatory stimulants. Seeing no immediate use, it's shelved.
On April 16 Hofmann accidentally absorbs a trace and experiences its effects. On April 19 he deliberately takes 250 µg, then cycles home as the world transforms — the first intentional LSD trip, now celebrated as Bicycle Day.
Sandoz markets LSD as Delysid, promoting it to psychiatry for psychotherapy and to let clinicians experience a temporary "model psychosis." Thousands of studies follow through the 1950s–60s.
LSD is explored in psycholytic and psychedelic therapy for alcoholism, anxiety and more. In parallel, the CIA's MK-Ultra program uses LSD in secret, often non-consensual and unethical mind-control experiments.
Figures like Timothy Leary and Ken Kesey carry LSD out of the lab and into the counterculture ("turn on, tune in, drop out"). It becomes a defining symbol of the era — and a target of backlash.
LSD is made illegal in the US and placed in Schedule I under the 1970 Controlled Substances Act. Legitimate research grinds to a near-total halt for decades.
A Swiss study (Gasser) on LSD for end-of-life anxiety marks the first modern controlled trial. Microdosing spreads culturally, and companies begin formal drug development — leading to today's Phase 3 programs.
LSD has re-entered mainstream drug development — and became the first psychedelic to reach Phase 3 trials for anxiety.
Disclaimer: This is an educational summary, not medical or legal advice, and does not endorse illegal activity. LSD carries real psychiatric, behavioural and legal risks; the clinical results come from careful screening, professional guidance and integration. Anyone considering use — especially with a mental-health history or on medication — should consult qualified medical professionals.